<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645252</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2997, 21621</org_study_id>
    <nct_id>NCT03645252</nct_id>
  </id_info>
  <brief_title>Sequence of Vessel Interruption and Circulating Tumor Cells in Surgical Lung Cancer</brief_title>
  <acronym>CTC-01</acronym>
  <official_title>Impact of the Sequence of Vessel Interruption During Major Pulmonary Resections for Non-small Cell Lung Cancer Based on Circulating Tumor Cells Detection Peroperatively in the Tumor-draining Pulmonary Vein: a Randomized Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to define the impact of the sequence of vessel interruption on change in CTC
      and CTC clusters density in the tumor-draining pulmonary vein between the period before
      surgical manipulation and before tumor-draining vein interruption.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in CTC density</measure>
    <time_frame>Within 96 hours after surgery</time_frame>
    <description>Changes in CTC count in 7.5 ml of blood sampled from the tumor-draining vein between the period before surgical manipulation (first sample) and before tumor-draining vein interruption (second sample).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CTC clusters density</measure>
    <time_frame>Within 96 hours after surgery</time_frame>
    <description>Changes in CTC clusters (or CTC micro-emboli defined as ≥3 contiguous CTC) count in 7.5 ml of blood sampled from the tumor-draining vein between the period before surgical manipulation (first sample) and before tumor-draining vein interruption (second sample).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years and 5 years after surgery</time_frame>
    <description>Disease free survival 2 years and 5 years after surgery and recurrence site (local or distant metastasis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years and 5 years after surgery</time_frame>
    <description>Overall survival 2 years and 5 years after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <condition>Lung Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Vein first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arteries before vein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vein interruption before any other surgical manipulation</intervention_name>
    <description>The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).
In the &quot;vein first&quot; group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner.</description>
    <arm_group_label>Vein first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arteries interruption before vein interruption</intervention_name>
    <description>The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).
In the &quot;arteries before vein&quot; group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above.</description>
    <arm_group_label>Arteries before vein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSCLC with preoperative pathological evidence,

          -  Pure solid nodule or part-solid (&gt;50%) ground glass nodule on CT scan

          -  Clinical stage tumor-1 to 3, clinical stage node-0, clinical stage metastasis-0,
             (except clinical stage tumor-3 for chest wall, pericardium or phrenic nerve invasion)

          -  Video-assisted thoracoscopic lobectomy or bi-lobectomy

        Exclusion Criteria:

          -  Pneumonectomy, segmentectomy, non anatomic resection

          -  History of thoracic surgery on the same side

          -  Necessity to perform a non-anatomic resection in addition to the lobectomy

          -  No preoperative histological diagnosis

          -  Pure ground glass nodule on CT scan

          -  Clinical stage tumor-4 or 3 for chest wall, pericardium or phrenic nerve invasion

          -  Clinical stage node ≥1

          -  Neoadjuvant therapy

          -  Second cancer or cancer in the past 5 years

          -  First approach through thoracotomy with ribs spreading

          -  Pregnancy, &lt;18 years of age

          -  Pulmonary adherences/symphysis found during surgery (impossible to perform the first
             blood sample without lung manipulation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Conti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche IUCPQ - Laval University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Conti Massimo, MD</last_name>
    <phone>+14186568711</phone>
    <phone_ext>3853</phone_ext>
    <email>massimo.conti@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Lavoie</last_name>
    <phone>+14186568711</phone>
    <phone_ext>5504</phone_ext>
    <email>marie.helene.lavoie@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Massimo Conti, MD</last_name>
      <phone>+14186568711</phone>
      <phone_ext>3853</phone_ext>
      <email>massimo.conti@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Jérémy Tricard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosaire Vaillancourt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Crosbie PA, Shah R, Krysiak P, Zhou C, Morris K, Tugwood J, Booton R, Blackhall F, Dive C. Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. J Thorac Oncol. 2016 Oct;11(10):1793-7. doi: 10.1016/j.jtho.2016.06.017. Epub 2016 Jul 25.</citation>
    <PMID>27468936</PMID>
  </results_reference>
  <results_reference>
    <citation>Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Tsubota N, Tsujimura T, Tabata C, Nakano T, Hasegawa S. Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact Cardiovasc Thorac Surg. 2014 Jun;18(6):775-83. doi: 10.1093/icvts/ivu048. Epub 2014 Mar 11.</citation>
    <PMID>24618055</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Massimo Conti</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

